Drug intelligence / Profile preview

INCB203954

Development stage: Preclinical
Lead developer: Incyte
Modality: Small Molecules

Overview

INCB203954 is an investigational, next-generation, selective small molecule inhibitor of mutant Janus kinase 2 (JAK2) V617F. Developed by Incyte, the compound is designed to target the JAK2V617F mutation, which is a common driver mutation in myeloproliferative neoplasms (MPNs). By selectively inhibiting the mutant form of the kinase, INCB203954 aims to provide disease-modifying activity in MPNs while potentially sparing wild-type JAK2 signaling, which is crucial for normal hematopoiesis. The drug is currently in preclinical development.

Targets

JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on INCB203954.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCB203954.